Lyra Therapeutics Inc (LYRA)

$0.29

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Lyra Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 146.0K → 532.0K (in $), with an average increase of 72.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -15.15M → -22.45M (in $), with an average decrease of 48.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 81.1% return, outperforming this stock by 171.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 227.9% return, outperforming this stock by 324.0%

Performance

  • $0.28
    $0.30
    $0.29
    downward going graph

    2.03%

    Downside

    Day's Volatility :5.58%

    Upside

    3.62%

    downward going graph
  • $0.25
    $6.79
    $0.29
    downward going graph

    12.69%

    Downside

    52 Weeks Volatility :96.27%

    Upside

    95.73%

    downward going graph

Returns

PeriodLyra Therapeutics IncIndex (Russel 2000)
3 Months
-94.48%
0.0%
6 Months
-94.46%
0.0%
1 Year
-90.58%
0.0%
3 Years
-96.13%
-21.0%

Highlights

Market Capitalization
17.8M
Book Value
$1.27
Earnings Per Share (EPS)
-1.17
Wall Street Target Price
1.25
Profit Margin
0.0%
Operating Margin TTM
-4421.81%
Return On Assets TTM
-38.1%
Return On Equity TTM
-95.93%
Revenue TTM
1.7M
Revenue Per Share TTM
0.03
Quarterly Revenue Growth YOY
29.799999999999997%
Gross Profit TTM
-34.2M
EBITDA
-71.6M
Diluted Eps TTM
-1.17
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.27
EPS Estimate Next Year
-1.06
EPS Estimate Current Quarter
-0.26
EPS Estimate Next Quarter
-0.26

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Lyra Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 331.03%

Current $0.29
Target $1.25

Technicals Summary

Sell

Neutral

Buy

Lyra Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lyra Therapeutics Inc
Lyra Therapeutics Inc
-6.16%
-94.46%
-90.58%
-96.13%
-98.43%
Moderna, Inc.
Moderna, Inc.
-16.37%
18.89%
-4.07%
-48.35%
748.18%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.16%
17.36%
52.58%
90.65%
268.9%
Novo Nordisk A/s
Novo Nordisk A/s
-0.29%
33.6%
81.13%
227.9%
496.35%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.03%
11.71%
40.03%
146.43%
177.11%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lyra Therapeutics Inc
Lyra Therapeutics Inc
NA
NA
NA
-1.27
-0.96
-0.38
NA
1.27
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lyra Therapeutics Inc
Lyra Therapeutics Inc
Buy
$17.8M
-98.43%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
748.18%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
268.9%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
496.35%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
177.11%
31.94
39.46%

Institutional Holdings

  • Perceptive Advisors LLC

    20.93%
  • Nantahala Capital Management, LLC

    4.63%
  • Samsara BioCapital, LLC

    4.56%
  • Point72 Asset Management, L.P.

    4.50%
  • VR Adviser, LLC

    4.23%
  • Vanguard Group Inc

    2.43%

Company Information

lyra therapeutics, inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. the company's xtreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. its product candidates include lyr-210 and lyr-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. the company was formerly known as 480 biomedical, inc. and changed its name to lyra therapeutics, inc. in july 2018. lyra therapeutics, inc. was founded in 2005 and is headquartered in watertown, massachusetts.

Organization
Lyra Therapeutics Inc
Employees
109
CEO
Dr. Harlan W. Waksal M.D.
Industry
Health Technology

FAQs